| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Biotin-COG1410 TFA targets apoptosis pathways through its parent compound COG1410, which is derived from apolipoprotein E (ApoE). ApoE is involved in lipid transport and has been implicated in neuroprotection, neuronal repair, and inflammatory responses in the central nervous system. By mimicking ApoE, COG1410 modulates apoptotic signaling pathways, contributing to its neuroprotective and anti-inflammatory actions.
|
|---|---|
| ln Vitro |
Cog1410 (1-25 μm; 48 h) inhibits BV2 microglia's generation and release of NO and TNFα [1].
In vitro studies with COG1410 (1-25 microM; 48 hours) demonstrate that it decreases the production and release of nitric oxide (NO) and tumor necrosis factor alpha (TNFalpha) in BV2 microglia cells. These effects indicate an anti-inflammatory mechanism of action, reducing key inflammatory mediators produced by activated microglia. Biotin-COG1410 TFA itself is used as a detection tool for these studies. |
| ln Vivo |
In mice, COG1410 (0.3-0.6 mg/kg; single intravenous injection) dramatically enhanced both long-term tests of spatial learning and memory and short-term tests of vestibular motor function [1]. In rats, COG1410 (0.8 mg/kg; single intravenous injection) decreases ipsilateral hemisphere infarct volume, lessens post-stroke motor asymmetry, and enhances vestibular motor function [2].
In vivo, COG1410 (0.3-0.6 mg/kg; single intravenous dose) exhibits significant improvement on a short-term test of vestibulomotor function and on a long-term test of spatial learning and memory in mice. At 0.8 mg/kg (single intravenous dose), it improves vestibulomotor function, decreases poststroke locomotor asymmetry, and reduces infarct volume of the ipsilateral hemisphere in rats. |
| Enzyme Assay |
Biotin-COG1410 TFA, containing a biotin tag, is utilized in binding studies through the biotin-streptavidin interaction. The biotin moiety allows for high-affinity capture of the peptide and its binding partners on streptavidin-coated surfaces or beads. This enables the isolation and identification of proteins or cellular components that interact with the COG1410 peptide, facilitating mechanistic studies of its neuroprotective effects.
|
| Cell Assay |
For cellular experiments, the biotinylated peptide can be added to cell cultures such as BV2 microglia or neuronal cell lines. Following incubation and cell lysis, the biotin-tagged peptide and its associated protein complexes can be pulled down using streptavidin-conjugated beads. The eluted samples are then analyzed by immunoblotting or mass spectrometry to identify interaction partners involved in apoptosis and inflammation signaling pathways.
|
| Animal Protocol |
Animal studies for COG1410 utilize mouse models of traumatic brain injury and rat models of focal brain ischemia. COG1410 is administered via intravenous injection at single doses ranging from 0.3 to 0.8 mg/kg. Endpoints include behavioral assessments of vestibulomotor function and spatial learning/memory (Morris water maze), as well as histopathological analysis of infarct volume and neuroinflammation markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Biotin-COG1410 TFA are not detailed in available standard product literature. As a biotinylated peptide derivative and research tool for neurological studies, comprehensive PK parameters such as half-life, clearance, and bioavailability have not been extensively characterized. The parent peptide COG1410 has been shown to exert effects following intravenous administration in animal models.
|
| Toxicity/Toxicokinetics |
Toxicological data for Biotin-COG1410 TFA have not been extensively reported in available literature. As a research-use peptide derived from apolipoprotein E, no specific acute or chronic toxicity studies are typically described for the biotinylated version. Standard laboratory safety precautions for handling peptide-based research reagents should be observed, including the use of appropriate personal protective equipment.
|
| References |
|
| Additional Infomation |
Biotin-COG1410 TFA is a biotin-labeled ApoE-derived peptide with the sequence Ac-AS-[Aib]-LRKL-[Aib]-Lys[Biotin]-RLL-NH2. The parent compound COG1410 has been studied for its effects in traumatic brain injury, focal brain ischemia, and retinal ganglion cell survival. The compound is available as a research tool for studying neuroprotection, apoptosis, and inflammation in neurological disease models. It is not approved for clinical use.
|
| Molecular Formula |
C74H135N23O16S.XC2HF3O2
|
|---|---|
| Related CAS # |
COG1410;878009-24-6
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
